#United States #Salt Lake City #Sera Prognostics #PreTRM Test #Mark Capone

Sera Prognostics Announces New Board Member

Sera Prognostics Inc., well-known as The Pregnancy Company®, has exciting news in the realm of maternal and neonatal health. On July 1, 2026, they will welcome Mark Capone to their Board of Directors, a strategic move intended to enhance their focus on improving pregnancy outcomes through innovative research and diagnostic solutions.

Mr. Capone brings over 40 years of healthcare experience to Sera, particularly within the diagnostics and life sciences sectors. His background includes a transformative tenure as Chief Executive Officer of Myriad Genetics, where he pioneered advancements in precision medicine and expanded the company’s molecular diagnostics offerings. This level of expertise is expected to contribute significantly to Sera’s future endeavors in maternal health.

Within Sera, Mr. Capone will provide guidance and insight as the company continues to develop products like their PreTRM® Test. This leading diagnostic tool employs a blood-based biomarker approach that allows for early risk assessment of preterm births in pregnant women. Such innovations are crucial considering the alarming statistics on preterm births, which are a leading cause of infant illness and death.

Mark Capone's Vision for Maternal Health

Mr. Capone states, "Sera is addressing a significant unmet need in maternal and fetal health, and I believe the company's proteomics‑based approach has the potential to meaningfully improve outcomes." His commitment to Sera's mission echoes the vital importance of understanding pregnancy risks early on.

Zhenya Lindgardt, President and CEO of Sera Prognostics, emphasized the importance of Capone’s role: "Mark's extensive experience in commercializing complex diagnostic products and understanding reimbursement environments will be critical as we aim to increase the adoption of the PreTRM® test." This indicates a clear alignment between Capone’s expertise and Sera’s objectives, as they work to enhance their market presence and drive further innovation.

Addressing Preterm Birth

The significance of Capone’s appointment becomes even clearer when we consider the broader context of preterm births in the United States. Official reports have shown that the country has persistently struggled with this issue, receiving a D+ grade for preterm births for four consecutive years. This situation emphasizes the need for strategic leadership and advanced diagnostic solutions in the realm of maternal health.

According to research, preterm birth—defined as any birth before 37 weeks’ gestation—can lead to serious long-term health complications for infants, including learning disabilities, cerebral palsy, and chronic respiratory illnesses. The healthcare costs associated with managing these complications can reach approximately $25 billion annually, making effective interventions essential not only for healthcare systems but also for the families impacted.

Sera Prognostics is committed to mitigating these issues by providing healthcare providers with critical information that can inform timely and personalized clinical decisions, ultimately leading to better health outcomes for mothers and their newborns.

Conclusion

The addition of Mark Capone to the Board of Directors at Sera Prognostics marks an important step forward in the company's journey. His authoritative voice in healthcare leadership, combined with Sera's innovative capabilities, signifies a strengthened effort to tackle some of the significant challenges facing maternal and neonatal health today. As the company moves forward, it remains dedicated to delivering pioneering solutions that can help change lives for the better, reinforcing their commitment to improving the future of maternal health care.

With Capone's insights and Sera’s innovative products like the PreTRM Test, the future looks promising for enhancing pregnancy care and ultimately improving the health of both mothers and infants.